BursteinHJ, EliasAD, RugoHS. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol2008; 26:1810–6.
2.
AdamsVR, LeggasM. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors, Clin Ther2007; 29:1338–53.
3.
NaranjoCA, BustoU, SellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30:239–45.
4.
KollmannsbergerC, SoulieresD, WongR, ScaleraA, GaspoR, BjarnasonG. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J2007; 1:S41–54.
5.
LammieA, DrobnjakM, GeraldW, SaadA, CoteR, Cordon-CardoC. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem1994; 42:1417–25.
6.
MoritaE, LeeDG, SugiyamaM, YamamotoS. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res1994; 286:273–7.
7.
WilgusTA, MatthiesAM, RadekKA. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol2005; 167:1257–66.
8.
MaharajAS, Saint-GeniezM, MaldonadoAE, D'AmorePA. Vascular endothelial growth factor localization in the adult. Am J Pathol2006; 168:639–48.
